AveXis, Inc. (NASDAQ: AVXS) Investor Investigation Over Possible Wrongdoing In Acquisition Announced

Investors who purchased shares of AveXis, Inc. (NASDAQ: AVXS) and currently hold any of those NASDAQ: AVXS shares have certain options and should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Affected Securities: 

An investigation on behalf of investors, who currently hold shares of AveXis, Inc. (NASDAQ: AVXS), was announced concerning whether the takeover of AveXis, Inc. is unfair to NASDAQ: AVXS stockholders.

The investigation by a law firm concerns whether certain officers and directors of AveXis, Inc. breached their fiduciary duties owed to NASDAQ: AVXS investors in connection with the proposed acquisition.

On April 09, 2018, AveXis, Inc. (NASDAQ:AVXS) announced that it has entered into an agreement and plan of merger with Novartis pursuant to which Novartis will acquire AveXis, Inc. for $218 per share or a total of $8.7 billion in cash.

However, the investigation concerns whether the offer is unfair to NASDAQ: AVXS stockholders. More specifically, the investigation concerns whether the AveXis Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

Shares of AveXis, Inc. (NASDAQ: AVXS) closed on Apri 18, 2018, at $209.60 per share.